Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | PDE1A | P54750 | 2/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13822677 | 0.83 | SMN1; SMN2 (0.54) | KDM1AMAOAMAOBCD274NAMPT | |
| SCHEMBL104956 | 0.82 | CD274 (0.51) | KDM1AMAOAMAOBADORA2BADORA2A | |
| SCHEMBL25523398 | 0.81 | ADRB2 (0.45) | CD274PDE1APDE1BPDE1CNAMPT | |
| SCHEMBL20618574 | 0.79 | CASR (0.53) | KDM1AMAOAMAOBADORA2ACASR | |
| SCHEMBL23757646 | 0.78 | ADRB2 (0.32) | ADORA2AADRB2CASR | |
| SCHEMBL23757520 | 0.78 | ADRB2 (0.32) | ADORA2AADRB2CASR | |
| SCHEMBL23757802 | 0.78 | ADRB2 (0.32) | ADORA2AADRB2CASR | |
| SCHEMBL23774891 | 0.78 | PDE1A (0.37) | PDE1APDE1BPDE1C | |
| SCHEMBL2461116 | 0.78 | CD274 (0.49) | KDM1AMAOAMAOBCD274NAMPT | |
| SCHEMBL23775042 | 0.76 | KDM1A (0.44) | KDM1AMAOAMAOBADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM1A 41/4885MAOA 4214/4885MAOB 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.